MGC Pharmaceuticals Limited (MXC.L) LSE

Currency In GBp

AD

MGC Pharmaceuticals Limited

Address

1202 Hay Street

West Perth, WA 6005

Australia

Phone

61 8 6382 3390

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

N/A

First IPO Date

February 09, 2021

Key Executives

NameTitlePayYear Born
Roby Reuven ZomerCo-Founder, Chief Executive Officer, MD & Executive Director183,3031980
Sasha FriedmanDeputy Chief Executive Officer0N/A
Yifat SteuerDeputy Chief Executive Officer & Chief Operating Officer0N/A
Nadya LisovoderChief Medical Officer0N/A
Tom CairnsChief Accounting Officer0N/A
Nicole Ann GodresseGlobal Chief Sales Officer0N/A
Sabina SuljakovicHead of the Quality Assurance Department0N/A
Yair TalChief Information Security Officer0N/A
Amir PolakChief Pharmaceutical Development Officer0N/A
Robert ClementsChief Commercial Officer0N/A
AD

Description

MGC Pharmaceuticals Limited, a biopharmaceutical firm, is engaged in the creation and provision of plant-derived medicines across Australia, Israel, and Slovenia. Its primary product pipeline features CimetrA, currently undergoing Phase III clinical trials for the treatment of early-stage COVID-19. Also in development is CannEpil, a Phase IIb cannabis-derived treatment designed for epilepsy that is resistant to other drugs, and CogniCann, which is in Phase II clinical trials for alleviating dementia symptoms. The company maintains research and development partnerships with the Royal Melbourne Institute of Technology and the University of Notre Dame. Furthermore, it collaborates with the Slovenian National Institute of Biology and the Neurosurgery Department at the University Medical Centre. Originally known as Erin Resources Limited, the company adopted its current name, MGC Pharmaceuticals Limited, in December 2015. Established in 2014, its main office is located in West Perth, Australia.

AD